aTyr Pharma (LIFE) Announces Earnings Results
aTyr Pharma (NASDAQ:LIFE) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01, Fidelity Earnings reports.
Shares of NASDAQ:LIFE opened at $0.51 on Tuesday. aTyr Pharma has a fifty-two week low of $0.38 and a fifty-two week high of $3.05. The stock has a market capitalization of $16.76 million, a P/E ratio of -0.27 and a beta of 2.41. The company has a current ratio of 5.38, a quick ratio of 5.38 and a debt-to-equity ratio of 0.26.
A number of equities research analysts have issued reports on LIFE shares. Zacks Investment Research downgraded shares of aTyr Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, January 16th. ValuEngine downgraded shares of aTyr Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, December 18th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $1.01.
aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.
Featured Story: Quick Ratio
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.